How Myeloma Response Criteria Measure Treatment Success

Myeloma response criteria are the standardized benchmarks doctors use to judge how well a multiple myeloma treatment is working, ranging from complete disappearance of detectable disease down to minimal or no improvement at all. The system most widely used today comes from the International Myeloma Working Group (IMWG), and it has been updated several times as newer drugs started pushing patients into deeper remissions than older therapies could achieve. Understanding these categories matters because the depth of your response directly affects how long remission lasts and, in many cases, overall survival.

How Response Is Measured

Multiple myeloma is a cancer of plasma cells, which normally produce antibodies. Myeloma cells churn out a single type of abnormal antibody, called a monoclonal protein or M-protein, that can be tracked in the blood and urine. The core of response assessment revolves around measuring this M-protein through lab tests: serum protein electrophoresis (SPEP), which separates proteins by size and charge to reveal an abnormal spike, and immunofixation electrophoresis (IFE), a more sensitive test that can detect smaller amounts of M-protein that SPEP misses.

Beyond these, the serum free light chain (sFLC) assay measures fragments of antibodies circulating in the blood. This test is especially important for patients whose myeloma produces only light chains rather than full antibodies, since those patients may not have a measurable M-protein spike on standard electrophoresis. Recent research supports incorporating serial sFLC measurements even in patients who do have measurable M-protein by electrophoresis, and some investigators argue that sFLC monitoring could replace the cumbersome 24-hour urine collection that has traditionally been part of response assessment.¹

Bone marrow biopsy rounds out the picture. Because myeloma lives primarily in the bone marrow, directly examining a sample of marrow tissue for the percentage and clonality of plasma cells is the only way to confirm the deepest levels of response. Standard bone marrow assessment is relatively insensitive, though, which is part of why newer technologies have been layered on top.

The Standard Response Categories

The IMWG response categories form a ladder, with each rung reflecting a deeper reduction in disease. The main tiers, from shallowest to deepest, are:

Minimal response (MR): A 25–49% reduction in serum M-protein. This category is mainly used in relapsed disease settings and is not considered a meaningful response in frontline treatment.
Partial response (PR): At least a 50% reduction in serum M-protein and at least a 90% reduction in 24-hour urine M-protein, or a drop to less than 200 mg per 24 hours.
Very good partial response (VGPR): M-protein is detectable by immunofixation but not by standard electrophoresis, or serum M-protein has dropped by 90% or more.
Complete response (CR): Negative immunofixation on both serum and urine, disappearance of any soft-tissue tumors, and fewer than 5% plasma cells in the bone marrow.
Stringent complete response (sCR): All the criteria for CR, plus a normal serum free light chain ratio and the absence of clonal plasma cells in the bone marrow as confirmed by immunohistochemistry or flow cytometry.

These definitions were refined over time as treatments improved. A decade ago, relatively few patients reached CR. With modern combination regimens, deep responses became common enough that the old categories no longer distinguished well between patients who were doing very well and those who were doing extraordinarily well.²

Does Deeper Response Actually Mean Longer Survival?

In general, yes, and the data on this are quite robust. After autologous stem-cell transplant, patients who achieved stringent complete response had a five-year overall survival rate of about 80%, compared with roughly 53% for those reaching conventional CR and 47% for near-CR. The median time before disease progression was 50 months for sCR patients versus around 20 months for those in CR or near-CR.³

That said, the value of stringent CR as a category has been debated. One analysis found that the free light chain ratio component of the sCR definition did not, by itself, reliably distinguish patients at different risk levels. What did matter was whether bone marrow flow cytometry detected residual clonal plasma cells. Even among patients classified as being in CR, about a third still had detectable clonal disease when assessed by sensitive flow cytometry, and those patients fared significantly worse.⁴ This finding helped push the field toward even more sensitive tools for measuring leftover disease.

A related nuance involves the free light chain ratio. Research has shown that an abnormal ratio caused by suppression of the uninvolved light chain, which can happen as a side effect of treatment-related immune suppression, should not be treated the same as an abnormal ratio caused by elevated involved light chains. Patients whose abnormal ratio was due to suppression actually had outcomes similar to those with a normal ratio, meaning they were being unfairly excluded from the sCR category.⁵

Minimal Residual Disease Testing

Minimal residual disease (MRD) testing represents the sharpest lens currently available for assessing response. Where standard response criteria can confirm the absence of M-protein in blood and urine, MRD testing looks for trace numbers of myeloma cells still lurking in the bone marrow at levels far below what conventional methods detect. The IMWG has defined MRD negativity as the absence of clonal plasma cells at a sensitivity of at least one in 100,000 cells, assessed by either next-generation flow cytometry (NGF) or next-generation sequencing (NGS).⁶

Next-generation flow cytometry uses panels of fluorescent antibodies that bind to surface markers on plasma cells, enabling a computer to sort normal from abnormal cells across millions of events in a single sample. A standardized approach developed by the EuroFlow consortium showed that about a quarter of patients classified as MRD-negative by older flow methods actually still harbored detectable disease when retested with the newer, more sensitive protocol. Patients who were truly MRD-negative by the updated method had substantially longer progression-free survival.⁷

The clinical impact of MRD status is striking. A meta-analysis pooling data from multiple studies found that MRD-negative patients had roughly double the median progression-free survival of MRD-positive patients (54 versus 26 months) and a meaningful overall survival advantage as well (98 versus 82 months).⁸ Those numbers make MRD negativity one of the strongest prognostic markers available in myeloma today.

Sustained MRD Negativity and Why Timing Matters

A single MRD-negative bone marrow result is encouraging, but what matters even more is whether that result holds up over time. A phase 2 study tracking newly diagnosed patients found that those who sustained MRD negativity for at least two years had no recorded disease progression during a subsequent follow-up period. In contrast, patients who initially tested MRD-negative but then lost that status were at very high risk of progression, even higher than patients who had been MRD-positive all along.⁹

This finding has practical implications. A one-time snapshot of MRD status may be misleading. Someone who tests negative early but converts to positive later is arguably in a more precarious position than a patient who never achieved MRD negativity in the first place, because the conversion signals that resistant clones are expanding. Serial MRD testing, repeating the assessment at planned intervals, gives clinicians a dynamic picture that a single test cannot provide. The IMWG now defines “sustained MRD negativity” as maintaining MRD-negative status confirmed at least one year apart.

Imaging in Response Assessment

Blood and bone marrow tests can miss disease that has escaped from the marrow into soft tissue or bone. Imaging fills that gap. PET/CT scanning, which detects metabolically active tissue, is the most established imaging modality for myeloma response assessment. A study standardizing PET response evaluation in newly diagnosed patients found that achieving a complete metabolic response, defined as myeloma-related activity in focal lesions and bone marrow falling below liver background levels, independently predicted better progression-free and overall survival.¹⁰

Whole-body diffusion-weighted MRI is an alternative that does not involve radiation and may be more sensitive for detecting marrow-based disease. This technique measures how freely water molecules move through tissue; cancerous marrow restricts water movement differently than healthy marrow. In responding patients, measurable changes in water diffusion tracked accurately with clinical response as defined by IMWG criteria, while non-responders showed the opposite pattern.¹¹ One limitation is that the technique performs best for focal lesions. Diffuse patterns of marrow involvement, where disease is spread evenly rather than concentrated in distinct spots, may not show the same clear changes during treatment.¹²

The IMWG has incorporated imaging into its deepest response category: “imaging-plus MRD negativity” requires both bone marrow MRD negativity at the standard sensitivity level and the disappearance of every area of abnormal tracer uptake on PET/CT (or equivalent imaging). This combined definition is the most stringent measure of disease control currently defined.

When Therapeutic Antibodies Muddy the Water

Modern myeloma therapy commonly includes anti-CD38 monoclonal antibodies like daratumumab and isatuximab. These drugs are themselves antibodies, and they circulate in the blood at concentrations high enough to show up on the same immunofixation tests used to track the patient’s own M-protein. Since daratumumab is an IgG-kappa antibody, it can produce a band on IFE that looks just like many patients’ own myeloma protein. If the lab cannot tell the drug from the disease, a patient who has actually cleared their M-protein might be misclassified as still having detectable disease, potentially preventing them from being scored as achieving CR.¹³

Reflex assays have been developed to solve this problem. For daratumumab, a specific antibody is added to the patient’s serum sample to shift the drug’s migration pattern on IFE, unmasking whether the patient’s own M-protein is still present underneath. A similar assay exists for isatuximab; in one study of patients with IgG-kappa myeloma who had a single suspicious band on standard IFE near the isatuximab migration zone, the drug-specific assay correctly identified residual M-protein in some samples while confirming that the band in others was purely drug interference.¹⁴ Without these specialized assays, a meaningful number of patients on anti-CD38 therapy would have their response depth underestimated.

Biochemical Relapse Versus Clinical Relapse

Response criteria also define when disease comes back. Progression in myeloma can be purely biochemical, meaning a rising M-protein level is the only sign, or clinical, meaning the patient develops symptoms like new bone lesions, anemia, kidney problems, or elevated calcium. The distinction matters for treatment decisions. In a real-world study of patients starting second-line lenalidomide-based therapy, those treated at the point of biochemical relapse rather than waiting for clinical relapse had a median progression-free survival of 24 months versus about 13 months. Early intervention at the biochemical stage was the single strongest predictor of longer remission on the next line of treatment.¹⁵

The difference carries through to overall survival as well. A separate analysis found that patients whose relapse was first identified as biochemical had a median overall survival from first relapse of about 59 months, compared with roughly 26 months for those who presented with clinical progression.¹⁶ The take-home message is clear: routine lab monitoring between clinic visits is not just paperwork. Catching a rising M-protein before symptoms develop can translate into months of additional survival.

Mass Spectrometry and the Push for Greater Sensitivity

Even the best standard lab tests have a floor of detection. IFE can reliably detect M-protein down to roughly 100–200 mg/L, but below that threshold, residual disease can go unnoticed. Mass spectrometry-based approaches are being developed to push detection limits further. One method, MALDI-TOF mass spectrometry, uses magnetic microparticles to enrich antibody fragments from a blood sample and then analyzes them by mass. In a study of newly diagnosed patients treated with daratumumab-based regimens, this method detected residual M-protein in nearly half of samples collected after patients had been classified as being in complete response by conventional tests. It also reliably distinguished the therapeutic antibody from the patient’s own M-protein in the vast majority of cases.¹⁷

An even newer iteration uses clonotypic peptide detection, where the unique amino acid sequence of a patient’s specific M-protein is identified once and then tracked with ultra-high sensitivity in subsequent blood draws. This blood-based approach could eventually complement or reduce the need for bone marrow biopsies, which are invasive and sample only a small area of marrow.¹⁸ These technologies are not yet part of the standard IMWG criteria, but they are actively being evaluated for incorporation into future guidelines.

MRD Negativity as a Regulatory Endpoint

Clinical trials in myeloma typically use progression-free survival or overall survival as their primary endpoints, but these require years of follow-up. As treatments improve, that wait grows longer, which paradoxically slows patients’ access to promising new drugs. An alternative is to use MRD negativity as an early surrogate endpoint, essentially asking whether clearing the bone marrow to undetectable levels reliably predicts that patients will live longer without their disease returning.

In April 2024, the FDA’s Oncologic Drugs Advisory Committee voted unanimously that MRD-negative complete response was reasonably likely to predict clinical benefit in myeloma and could be used to support accelerated drug approval.¹⁹ If MRD negativity becomes an accepted approval endpoint, new therapies could reach patients years sooner than they would under the traditional model of waiting for survival data to mature. For patients and clinicians alike, this shift represents a direct practical consequence of how response criteria have evolved.

Quality of Life and What the Numbers Miss

Response categories capture tumor biology, but they do not directly measure how the patient feels. Research into health-related quality of life in myeloma has found that over half of patients who responded to treatment reported meaningful improvements across all quality-of-life domains, including physical function, pain, fatigue, and disease-related symptoms. On the other hand, disease progression was associated with worsening scores across the board, not just in myeloma-specific symptoms but in general well-being too.²⁰

This matters because a deep laboratory response that comes at the cost of severe treatment toxicity may not translate into a better lived experience. Two patients can both achieve VGPR on paper but have very different day-to-day realities depending on the side-effect burden of their regimens. Clinical trials are increasingly asked to report patient-reported outcome data alongside traditional response rates, and interpreting those outcomes in the context of response depth adds a layer of information that lab values alone cannot provide. For patients reviewing their own results, response criteria are a crucial part of the story but never the whole story.

Non-Secretory Myeloma and Other Edge Cases

About 1–5% of myeloma patients have non-secretory disease, meaning their myeloma cells produce little or no measurable M-protein. The standard response criteria, built around tracking M-protein, are of limited use for these patients. Response assessment in non-secretory myeloma relies more heavily on bone marrow biopsy, imaging, and serum free light chains when detectable. MRD testing by flow cytometry or sequencing is especially valuable here, because it provides a direct marrow-based measure that does not depend on secreted protein at all.

Another edge case involves patients whose myeloma produces only free light chains without intact immunoglobulin. The serum free light chain assay is their primary monitoring tool, but treatment-related suppression of the uninvolved light chain can distort the ratio and give a misleading picture of residual disease.²¹ Clinicians working with these patients learn to read the absolute involved light chain level alongside the ratio, rather than relying on the ratio alone.